ALT/AST determinations while patients received biological DMARDs other than TNF inhibitors (eg, anakinra, abatacept, rituximab) were excluded from analysis, as were tests when patients were not ...
Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZA™ (vimseltinib), a kinase ...
JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated ...
Alt.Latino The global Latinx community is evolving and growing fast.Alt.Latino is here to celebrate it and all of its nuances through music. Each episode, NPR Music's Felix Contreras and Anamaria ...
In summary, enalapril significantly mitigated multiple pathological markers associated with aging, including lipid droplets, amyloid, glycogen deposition, and fibrosis, in the brain, kidneys, liver, ...
GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback